Identification of biomarkers for the diagnosis in colorectal polyps and metabolic dysfunction-associated steatohepatitis (MASH) by bioinformatics analysis and machine learning

被引:1
|
作者
Geng, Ying [1 ]
Li, Yifang [1 ]
Liu, Ge [1 ]
Jiao, Jian [1 ]
机构
[1] Jilin Univ, China Japan Union Hosp, Dept Gastroenterol & Hepatol, Changchun 130033, Peoples R China
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
关键词
Colorectal polyps; Metabolic dysfunction associated steatohepatitis (MASH); Bioinformatics analysis; Machine learning; Bile acids; FATTY LIVER-DISEASE; COLON-CANCER; CELLS; EXPRESSION; MIGRATION; PATHWAY; S100P; ACTIVATION; INHIBITOR; RECEPTORS;
D O I
10.1038/s41598-024-81120-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Colorectal polyps are precursors of colorectal cancer. Metabolic dysfunction associated steatohepatitis (MASH) is one of metabolic dysfunction associated fatty liver disease (MAFLD) phenotypic manifestations. Much evidence has suggested an association between MASH and polyps. This study investigated the biomarkers of MASH and colorectal polyps, and the prediction of targeted drugs using an integrated bioinformatics analysis method. Differentially expressed genes (DEGs) analysis and weighted gene co-expression network analysis (WGCNA) were performed on GSE89632 and GSE41258 datasets, 49 shared genes revealed after intersection. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses depicted they were mainly enriched in apoptosis, proliferation and infection pathways. Machine learning algorithms identified S100P, FOXO1, and LPAR1 were biomarkers for colorectal polyps and MASH, ROC curve and violin plot showed ideal AUC and stable expression patterns in both the discovery and validation sets. GSEA analysis showed significant enrichment of bile acid and fatty acid pathways when grouped by the expression levels of the three candidate biomarkers. Immune infiltration analysis showed a significant infiltration of M0 macrophages and Treg cells in the colorectal polyps group. A total of 9 small molecule compounds were considered as potential chemoprevention agents in MASH and colorectal polyps by using the CMap website. Using integrated bioinformatics analysis, the molecular mechanism between MASH and colorectal polyps has been further explored.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Circulating Neutrophil Profiles Undergo a Dynamic Shift during Metabolic Dysfunction-Associated Steatohepatitis (MASH) Progression
    Maretti-Mira, Ana C.
    Salomon, Matthew P.
    Chopra, Shefali
    Yuan, Liyun
    Golden-Mason, Lucy
    BIOMEDICINES, 2024, 12 (05)
  • [32] Role of Saroglitazar in the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in nondiabetic patients: a prospective observational study
    Kumar, Jata Shankar
    Bhardwaz, Priyanshu
    Kar, Premashis
    JOURNAL OF HEPATOLOGY, 2024, 80 : S609 - S610
  • [33] Focused Recommendations for the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Advanced Practice Providers in the United States
    Lam, Brian P.
    Bartholomew, Jessica
    Bau, Sherona
    Gilles, Hochong
    Keller, Andrea
    Moore, Ann
    Nader, Khalil
    Richards, Lisa
    Henry, Linda
    Younossi, Zobair M.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2025, 59 (04) : 298 - 309
  • [34] Thymidine Phosphorylase Imaging Probe for Differential Diagnosis of Metabolic dysfunction-associated Steatohepatitis
    Higashikawa, Kei
    Uehara, Riho
    Horiguchi, Sawako
    Shibata, Yuki
    Okubo, Naoto
    Mizuno, Yuki
    Yasui, Hironobu
    Ohnishi, Shunsuke
    Takeda, Hiroshi
    Kuge, Yuji
    MOLECULAR IMAGING AND BIOLOGY, 2024, 26 (06) : 1036 - 1045
  • [35] Identification of serum metabolome signatures associated with hepatocellular carcinoma in metabolic dysfunction-associated steatohepatitis
    Komori, Atsumasa
    Matsumoto, Kosuke
    Kugiyama, Yuki
    Suehiro, Tomoyuki
    Motoyoshi, Yasuhide
    Saeki, Akira
    Nagaoka, Shinya
    Yamasaki, Kazumi
    Yatsuhashi, Hiroshi
    JOURNAL OF HEPATOLOGY, 2024, 80 : S542 - S542
  • [36] A machine learning approach to identify patient features associated with metabolic dysfunction-associated steatohepatitis from the United Kingdom biobank
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Karamchandani, Umesh
    Romero, Jonathon
    Henstock, Peter
    Emir, Birol
    Sanyal, Arun J.
    JOURNAL OF HEPATOLOGY, 2024, 80 : S533 - S534
  • [37] Identification of biomarkers associated with diagnosis of postmenopausal osteoporosis patients based on bioinformatics and machine learning
    Huang, Xinzhou
    Ma, Jinliang
    Wei, Yongkun
    Chen, Hui
    Chu, Wei
    FRONTIERS IN GENETICS, 2023, 14
  • [38] Identification of biomarkers associated with diagnosis of acute lung injury based on bioinformatics and machine learning
    Jing, Hekun
    Chen, Xiaorui
    Wang, Daoxin
    MEDICINE, 2023, 102 (33) : E34840
  • [39] THERAPEUTIC HORIZONS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE( MASLD) & METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS( MASH): A SYSTEMATIC REVIEW OF CURRENT TREATMENT OPTION
    Moliya, Pratiksha
    Al-Obaidi, Hasan
    Patel, Pranav
    Patel, Raj
    Parikh, Charmy
    Joy, Melvin
    HEPATOLOGY, 2024, 80
  • [40] Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective
    Younossi, Zobair M.
    Razavi, Homie
    Sherman, Michael
    Allen, Alina M.
    Anstee, Quentin M.
    Cusi, Kenneth
    Friedman, Scott L.
    Lawitz, Eric
    Lazarus, Jeffrey V.
    Schuppan, Detlef
    Romero-Gomez, Manuel
    Schattenberg, Joern M.
    Vos, Miriam B.
    Wong, Vincent Wai-Sun
    Ratziu, Vlad
    Hompesch, Marcus
    Sanyal, Arun J.
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025,